Comparison of mitotic index, in vitro @entity1603 labeling, and @entity1758 assays to quantitate proliferation in XXXX .

@entity1 @entity1603 @entity0 @entity5 @entity1758
PURPOSE: To investigate the hypothesis that in vitro @entity1603 ( @entity1603 ) labeling might be superior to @entity1758 immunostaining for prognostic value, because it more selectively labels cells during the S phase. METHODS: Four hundred eighty-six @entity1 with @entity0 (59% lymph node-negative, 41% lymph node-positive) surgically excised between 1988 and 1993 (median follow-up, 62 months) were evaluated for cellular proliferation using prospective in vitro @entity1603 uptake assays, retrospective mitotic indices, and @entity1758 labeling. RESULTS: @entity1758 , @entity1603 labeling, and mitotic index-derived proliferation data were highly correlated. Each was similarly associated with most other markers of prognosis, although these relationships were not identical. By univariate analysis, nodal status was the most significant prognostic variable for all @entity1 . Higher @entity1603 labeling index, @entity1758 immunolabeling, and mitotic index were also associated with shortened disease-free survival (DFS) and disease-specific survival for the entire @entity1 group, as well as for node-negative @entity1 . The association between cellular proliferation and survival was much weaker for node-positive @entity1 . Multivariate models confirmed that nodal status, @entity5 size, and proliferation data predicted survival in all @entity1 as well as those with node-negative disease, although @entity1758 was somewhat more closely associated with outcome than mitotic index or in vitro @entity1603 data. For @entity1 with T1NOMO disease (n = 172), the only significant predictors of DFS were proliferation rate (mitotic index or @entity1758 ) and @entity5 grade. CONCLUSIONS: Proliferation rate predicts recurrence and survival in @entity0 . This effect is more pronounced in node-negative @entity1 . In vitro @entity1603 data are not superior to @entity1758 and mitotic counting.
